Andreia Pereira Barateiro
PhD (2012) in Pharmacy (Cellular and Molecular Biology), Faculdade de Farmácia, Universidade de Lisboa
Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
Multiple sclerosis (MS) pathology is characterized by neuroinflammation and demyelination. Recently, the inflammatory molecule S100B was identified in cerebrospinal fluid and serum of MS patients. Nevertheless, increased S100B levels released upon injury may exacerbate tissue damage during an MS episode or delay the following remyelination.
My principal interest is to explore if S100B can be used as a biomarker of MS diagnosis and progression, and as a potential therapeutic target to reduce damage and/or improve recovery during the course of MS.
Santos G, Barateiro A, Gomes C, Brites D, Fernandes A. Impaired oligodendrogenesis and myelination by elevated S100B levels during neurodevelopment. Neuropharmacol 2018; 129: 69-83.
Barateiro A, Afonso V, Santos G, Cerqueira JJ, Brites D, van Horssen J, Fernandes A. S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis. Mol Neurobiol 2016; 53: 3976-91.
Barateiro A, Chen S, Yueh MF, Fernandes A, Domingues HS, Relvas J, Barbier O, Nguyen N, Tukey RH, Brites D. Reduced Myelination and Increased Glia Reactivity Resulting from Severe Neonatal Hyperbilirubinemia. Mol Pharmacol 2016; 89: 84-93.
Barateiro A, Domingues HS, Fernandes A, Relvas JB, Brites D. Rat cerebellar slice cultures exposed to bilirubin evidence reactive gliosis, excitotoxicity and impaired myelinogenesis that is prevented by AMPA and TNF-a inhibitors. Mol Neurobiol 2014; 49: 424-39.
Barateiro A, Miron VE, Santos SD, Relvas JB, Fernandes A, ffrench-Constant C, Brites D. Unconjugated bilirubin restricts oligodendrocyte differentiation and axonal myelination. Mol Neurobiol 2013; 47: 632-44.